

17648 U.S. STG  
09/26/03

Place a plus (+) inside this box



PTO/SB/05 (03-01)  
Approved for use through 10/31/2002. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	10624-133-999	Total Pages	429
First Named Inventor or Application Identifier			
Bhagwat et al.			
Express Mail Label No.	EV 335 857 018 US		

## APPLICATION ELEMENTS

See MPEP chapters 600 concerning utility patent application contents.

Address to:

Commissioner for Patents  
P.O. Box 1450  
Mail Stop PATENT APPLICATION  
Alexandria, VA 22313-1450

- ☒ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
- ☐ Applicant claims Small Entity status, see 37 C.F.R. § 1.27
- ☒ Specification  
(Total Pages 412)  
(preferred arrangement set forth below, MPEP 1503.01)
  - Descriptive title of the Invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description of the Invention (including drawings, if filed)
  - Claim(s)
  - Abstract of the Disclosure
- ☐ Drawing(s) (35 USC 113)  
(Total Sheets )
- ☒ Declaration and Power of Attorney  
(Total Sheets 4)
  - a. ☐ Newly executed (original or copy)
  - b. ☒ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)
  - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
- ☐ Application Data Sheet. See 37 CFR 1.76

- ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
- ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. ☐ Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ paper
  - c. ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet & document(s))
- ☐ 37 CFR 3.73(b) Statement (when there is an assignee)
- ☐ English Translation Document (if applicable)
- ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ A Copy of IDS References AD and AE
- ☒ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
- ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
- ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(i). Applicant must attach form PTO/SB/35 or it's equivalent
- ☐ Other:

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior pending application No.: 09/910,950 filed July 23, 2001, which claims the benefit of provisional application no. 60/221,799, filed July 31, 2000.

Prior application information:

Examiner: L. Stockton

Group Art Unit: 1626

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

☒ Customer Number

20583

Insert Customer No. or Attach bar code label here

or ☐ Correspondence address below

NAME

ADDRESS

CITY

COUNTRY

STATE

TELEPHONE

ZIP CODE

FAX

NY2: 1466968.1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Prior application: Examiner L. StocktonArt Unit 1626Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR § 1.53(b), of pending prior U.S. Application No. 09/910,950, filed July 23, 2001, which claims the benefit of U.S. Provisional Application No. 60/221,799, filed July 31, 2000, the disclosure of each is incorporated by reference in the present application in its entirety.

Shripad S. Bhagwat; Yoshitaka Satoh; Steven Sakata; Christopher Buhr; Ronald Albers; John Sapienza;  
of Veronique Plantevin; Qi Chao; Kiran Sahasrabudhe; Rachel Ferri

(inventor(s) currently of record in prior application)

INDAZOLE DERIVATIVES AS JNK INHIBITORS AND COMPOSITIONS AND METHODS RELATED  
for THERETO

(title of invention)

1. ☒ The filing fee is calculated below:

**PATENT APPLICATION FEE VALUE**

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	87	- 20	67	\$18.00 each	\$ 1206.00
Independent	3	- 3	0	\$86.00 each	\$ 0.00
Minimum Fee					\$ 750.00
Multiple Dependency Fee If Applicable (\$280.00)					\$ 0.00
<b>Total</b>					\$ 1956.00
Applicant qualifies for the 50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					\$ 0.00
<b>Total Filing Fee</b>					\$ 1956.00

2. ☒ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this document is enclosed.
3. ☐ Amend the specification by inserting before the first line the following sentence: This is a continuation of application no. filed which is incorporated by reference herein in its entirety.
- 4a. ☐ Drawings are enclosed.
- 4b. ☐ Informal drawings are enclosed.

- 5a. ☐ Priority of application no. filed on in is claimed under 35 U.S.C. §119.
- 5b. ☐ The certified copy has been filed in prior application no. , filed .
6. ☒ The prior application is assigned of record from Shripad S. Bhagwat; Yoshitaka Satoh; Steven Sakata; Ronald Albers; John Sapienza; Veronique Plantevin; Qi Chao; Kiran Sahasrabudhe; and Rachel Ferri to Signal Pharmaceuticals, Inc. (Reel/Frame 012692/0030) and is also assigned of record from Chris Buhr to Signal Pharmaceuticals, Inc. (Reel/Frame 012680/0489)
- 7a. ☒ A copy of the Declaration for Non-Provisional Patent Application (two counterparts) filed in the prior application no. no. 09/910,950 filed on July 23, 2001, is enclosed.
- 7b. ☐ Power of Attorney
8. ☐ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no., filed on be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. is enclosed.
9. ☐ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. is the same as the content of the computer readable form submitted in application no. .
10. ☐ DO NOT PUBLISH. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
11. ☒ Additional Enclosures: Information Disclosure Statement; Form PTO-1449 listing references AA-BS; a copy of references AD and AE.

Respectfully submitted,

Date September 26, 2003

*Anthony M. Insogna, N.Y. No. 35,203*  
*By: Matthew E. Long, N.Y. No. 36,343*  
 35,203  
 Anthony M. Insogna  
 PENNIE & EDMONDS LLP  
 1155 Avenue of the Americas  
 New York, New York 10036-2711  
 (212) 790-9090  
 (Reg. No.)